111个探针的低甲基化预示胶质母细胞瘤预后不良。
Hypomethylation of 111 Probes Predicts Poor Prognosis for Glioblastoma.
作者信息
Chen Qi, Zhao Min, Yin Chengliang, Feng Shiyu, Hu Jian, Zhang Qiang, Ma Xiaodong, Xue Wanguo, Shi Jinlong
机构信息
National Engineering Laboratory for Medical Big Data Application Technology, Chinese PLA General Hospital, Beijing, China.
Medical Big Data Center, Chinese PLA General Hospital, Beijing, China.
出版信息
Front Neurosci. 2019 Oct 25;13:1137. doi: 10.3389/fnins.2019.01137. eCollection 2019.
Glioblastoma (GBM) is a complicated brain tumor with heterogeneous outcome. Identification of effective biomarkers is an urgent need for the treatment decision-making and precise evaluation of prognosis. Based on a relatively large dataset of genome-wide methylation (138 glioblastoma patients), a joint-score of 111 methyl-probes was found to be of statistical significance for prognostic evaluation. Low joint-score were significantly associated with adverse outcomes (OS: < 0.001, PFS: = 0.03). Multivariable analyses adjusted for known risk factors confirmed the low joint-score of 111 methyl-probes as a high risk factor. The prognostic value of the methylated joint-score was further validated in another dataset of glioblastoma patients (OS: = 0.006). Additionally, variance analysis revealed that aberrant genetic and epigenetic alterations were significantly associated with the joint-score of those methyl-probes. In conclusion, our results supported the joint-score of 111 methyl-probes as a potential prognosticator for the precision treatment of glioblastoma.
胶质母细胞瘤（GBM）是一种预后各异的复杂脑肿瘤。识别有效的生物标志物对于治疗决策和精确评估预后至关重要。基于一个相对较大的全基因组甲基化数据集（138例胶质母细胞瘤患者），发现111个甲基化探针的联合评分对预后评估具有统计学意义。低联合评分与不良预后显著相关（总生存期：<0.001，无进展生存期：=0.03）。对已知风险因素进行校正的多变量分析证实，111个甲基化探针的低联合评分是一个高风险因素。甲基化联合评分的预后价值在另一组胶质母细胞瘤患者数据集中得到进一步验证（总生存期：=0.006）。此外，方差分析显示，异常的基因和表观遗传改变与这些甲基化探针的联合评分显著相关。总之，我们的结果支持将111个甲基化探针的联合评分作为胶质母细胞瘤精准治疗的潜在预后指标。
Zotero 插件